FV2GP
MCRB icon

Flagship Ventures 2007 General Partner’s Seres Therapeutics MCRB Stock Holding History

Flagship Ventures 2007 General Partner’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$21M Hold
29,965
– – 13.8% 2
2015
Q3 		$17.8M Hold
29,965
– – 11.17% 2
2015
Q2 		$24.9M Buy
+29,965
New +$26.1M 10.1% 2

Other funds holding MCRB

FVFIGP
Flagship Ventures Fund IV General Partner Cambridge, Massachusetts $585M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Flagship Ventures 2007 General Partner's MCRB Position: Q4 2015 in Review

Flagship Ventures 2007 General Partner held its Seres Therapeutics (MCRB) position steady in Q4 2015 at 29,965 shares worth $21M. The position accounts for 13.8% of the portfolio, ranked #2.

Flagship Ventures 2007 General Partner first reported a position in MCRB in Q2 2015 and has held it in 3 quarters since. The position peaked at $24.9M in Q2 2015. 69 funds tracked by Wall St. Rank hold MCRB as of Q4 2015.

  • Flagship Ventures 2007 General Partner held 29,965 shares of Seres Therapeutics worth $21M as of Q4 2015.
  • Flagship Ventures 2007 General Partner left its Seres Therapeutics share count unchanged in Q4 2015.
  • Seres Therapeutics made up 13.8% of Flagship Ventures 2007 General Partner's portfolio in Q4 2015, its #2 holding.
  • Flagship Ventures 2007 General Partner first reported a position in Seres Therapeutics in Q2 2015 and has held it in 3 quarters since.
  • Flagship Ventures 2007 General Partner's Seres Therapeutics position peaked at $24.9M in Q2 2015.
  • 69 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2015.

Based on Flagship Ventures 2007 General Partner's 13F filing for Q4 2015, filed 12 Feb 2016.